// you’re reading...

General Biotechnology

Enigmatic ImClone

By Yali ⋅ October 14, 2003 ⋅ Email This Post Email This Post ⋅ Print This Post Print This Post ⋅ Post a comment

Enigmatic ImClone
Rarely has a company reeling from corporate malfeasance been on the receiving end of so much good news. But such is the case with ImClone Systems, as investors struggle for clues on the long-term direction of this enigma.

Print This Post

Discussion

No comments for “Enigmatic ImClone”

Post a comment

Building Biotechnology - Starting, Managing, and Understanding Biotechnology Companies   The Business of Biotechnology - Profit From the Growing Influence of Biotechnology
Best Practices in Biotechnology Business Development Best Practices in Biotechnology Education
Journal of Commercial Biotechnology 
DrugPatentWatch.com